Reasons for withdrawal were poor compliance (n = 10), the patient's decision (n = 3), and asthma that was too unstable (n = 2). "Intention to treat" analysis showed that the median dose of beclomethasone causing hypothalamo-pituitary-adrenal suppression was similar in the two groups (3.25 mg in S v 3 0 mg in MDI; 95% confidence interval (CI) for difference -1-0 to 1-0 mg). At 2 mg/day of beclomethasone most patients in both groups had well controlled asthma and there were no differences in symptoms or peak flow between the groups. Good control at this dose did not permit conclusions to be drawn about the efficacy of higher doses. Conclusions There is wide interindividual variation in the dose of beclomethasone dipropionate causing hypothalamopituitary-adrenal suppression. Whether or not a spacer is used, doses higher than the currently accepted maximum of 2 mg/day can be taken by many adults with asthma without causing subnormal function of the hypothalamo-pituitaryadrenal axis. Whether these higher doses are more effective in controlling asthma remains to be established.
95% confidence interval (CI) for difference -1-0 to 1-0 mg). At 2 mg/day of beclomethasone most patients in both groups had well controlled asthma and there were no differences in symptoms or peak flow between the groups. Good control at this dose did not permit conclusions to be drawn about the efficacy of higher doses. Conclusions There is wide interindividual variation in the dose of beclomethasone dipropionate causing hypothalamopituitary-adrenal suppression. Whether or not a spacer is used, doses higher than the currently accepted maximum of 2 mg/day can be taken by many adults with asthma without causing subnormal function of the hypothalamo-pituitaryadrenal axis. Whether these higher doses are more effective in controlling asthma remains to be established. (Thorax 1993; 48:233-238) High dose inhaled corticosteroids (more than 1 mg beclomethasone dipropionate or budesonide daily) are being used more frequently in the treatment of chronic asthma. Early studies1 2 suggested that most patients taking 2 mg beclomethasone had impaired function of the hypothalamo-pituitary-adrenal axis and thus 2 mg/day became the maximum recommended dose. In a recent survey, however, of adults with asthma taking long term high dose inhaled corticosteroids3 most of those inhaling 2 mg beclomethasone daily were found to have normal hypothalamo-pituitaryadrenal function. In that study only a few patients were using large volume spacers and there is now evidence that these devices can protect against the adverse effects of beclomethasone on the hypothalamo-pituitary-adrenal axis.7 Our study has attempted to answer three questions: (1) What daily dose of beclomethasone dipropionate will cause subnormal hypothalamo-pituitaryadrenal function in asthmatic adults having long term treatment? (2) Can the protective effect of a spacer shown in open studies of asthmatic patients457 be confirmed in a randomised, double blind study? (3) Is administration of high dose inhaled corticosteroid via a spacer clinically more effective than conventional treatment with a metered dose aerosol?
Methods
The study was of randomised, double blind, double dummy, parallel group design.
Patients were eligible if they fulfilled the following criteria: (1) who had normal hypothalamo-pituitaryadrenal function were randomised to receive increasing doses of beclomethasone dipropionate from a metered dose or without a large volume spacer (Volumatic). The daily dose was increased by 0 5 mg at monthly intervals until hypothalamo-pituitary-adrenal suppression (results of two or more tests subnormal) developed or a dose of 5 mg daily was reached. Aerosols delivering 250 ,ug per actuation were used and therefore any patient reaching the highest dose was taking 40 puffs (20 active drug and 20 placebo) a day. The dosing frequency was twice daily initially but was increased to three times if a total dose of 14 puffs daily was reached. Patients were instructed to use the spacer first and to take two inhalations from the spacer after each actuation of the aerosol, each inhalation to be followed by a breath hold of five seconds. No instructions regarding mouth rinsing were given. Each month patients attended for clinic visits at 0900 h and collected urine for 24 hours before each visit. On these days they took the usual morning doses of inhaled steroid and placebo before attending. Immediately after venesection for the 0900 h cortisol estimation 0-25 mg tetracosactrin was given intramuscularly and a further blood sample taken after 30 minutes. A throat swab was taken for culture for fungi and patients were questioned about any adverse events. Diary cards were checked and an assessment of compliance with the study medication was made from the remaining doses in returned canisters.
All patients gave written informed consent and the study was approved by the regional ethics committee.
STATISTICAL ANALYSIS
The study was analysed on the basis of intention to treat. Of these 38 patients, 23 (14 S, 9 MDI) completed the study, one of whom (S) achieved the highest dose of 5 mg daily without evidence of hypothalamo-pituitary-adrenal suppression. A second patient (MDI) also achieved the highest dose but proved to be not fully compliant. Another six patients (3 S, 3 MDI) were withdrawn because of undercompliance with higher doses and three (2 S) because of non-attendance. Three (2 MDI) withdrew from the study and two (MDI) were withdrawn because of persistently troublesome asthma symptoms.
HYPOTHALAMO-PITUITARY-ADRENAL FUNCTION TESTS
The outcome in the 49 patients included in the intention to treat analysis is shown in the figure. The cumulative numbers of patients withdrawn at each visit, either because of hypothalamo-pituitary-adrenal suppression or for other reasons, are shown according to treatment group. Analysis of the results of hypothalamo-pituitary-adrenal tests at each clinic visit suggested that there was no difference between the proportions of patients in each of the two groups who had hypothalamo-pituitary-adrenal suppression; on the basis of the last available results for each patient the proportions were 65% in S v 66-7% in MDI (treatment difference 1-7%, 95% confidence intervals -30% to 33 4%, p = 0 92). The dose of beclomethasone causing hypothalamo-pituitary-adrenal suppression varied widely in both groups, ranging from 2'0 to 5 0 mg in the spacer group and from 1-5 to 4-5 mg in the MDI group. There was no difference in the median dose between the two groups (3-25 mg in S v 3 0 mg in MDI; p = 0-99, 95% confidence intervals for difference -1I0 to 1 0 mg).
DEVELOPMENT OF HYPOTHAIAMO-PITUITARY-ADRENAL SUPPRESSION Twenty nine of the 50 patients had evidence of hypothalamo-pituitary-adrenal suppression (results in at least two of the three screening tests subnormal), either at the initial screening or during the study. In 17 (59%) of these patients all three tests yielded subnormal results. In the remaining 12 hypothalamopituitary-adrenal suppression was diagnosed on the basis of abnormal results for 0900 h cortisol and post-tetracosactrin cortisol in five, for 0900 h cortisol and urinary free cortisol in three, and for post-tetracosactrin cortisol and urinary free cortisol in four. No individual test was superior in detection of hypothalamo-pituitary-adrenal suppression. In most patients the pattern of suppression was reduced urinary cortisol excretion and 0900 h serum cortisol concentration with preservation of the response to tetracosactrin (an increment of at least 200 nmol/l) but failure to achieve a value of 500 nmol/l or more because of a reduced basal value. The increment in cortisol was below 200 nmol/l in only nine (31%) patients. Differences in the development of hypothalamo-pituitary-adrenal suppression were observed between patients: in some the serum and urinary cortisol declined progressively as the dose of beclomethasone was increased but in others a threshold effect was seen, the levels tending to remain well within normal ranges until a critical dose was reached. Most patients in both groups reported improvement in asthma symptoms when the dose of beclomethasone dipropionate was increased from 1-5 to 2-0 mg daily. Table 3 shows the symptom scores and mean peak flow rates in the two groups while they were taking 2 mg beclomethasone. At Systemic adverse effects of corticosteroids were observed in two patients (one in each treatment group). Both developed spontaneous bruising while taking beclomethasone dipropionate in doses (3*5 and 4-5 mg/day) that caused subnormal hypothalamopituitary-adrenal function. Of the patients withdrawn from the study because of hypothalamo-pituitary-adrenal suppression, none developed symptoms of adrenal insufficiency with reduction in the dose of inhaled steroid.
Discussion
This study did not confirm that large volume spacer devices reduce the systemic effects of beclomethasone dipropionate inhaled in large doses, as measured by changes in hypothalamo-pituitary-adrenal axis function. The median dose of beclomethasone causing hypothalamo-pituitary-adrenal suppression was 3-25 mg when the drug was administered through the spacer and 3-0 mg when administered by the conventional metered dose aerosol. The wide 95% confidence intervals, however, indicate a high probability of type 2 error (the true difference between the two Table 3 Asthma symptoms in patients inhaling 2 mg beclomethasone dipropionate with and without a large volume spacer (median values except where otherwise specified) treatments, if one exists, could be as much as 1 mg in favour of either mode of inhalation). The long duration of the study of up to nine months for an individual patient coupled with the requirement for patients to take an increasingly large number of puffs of trial medication resulted in a high withdrawal rate. In addition, there was a large variation between individuals in the extent to which the hypothalamo-pituitary-adrenal axis was suppressed by exogenous steroids. These two factors meant that insufficient patients achieved the study's endpoint to ensure adequate power.
For similar reasons and because asthma was generally well controlled while patients were taking 2 mg/day, no conclusion can be drawn about whether high dose beclomethasone dipropionate is more effective if inhaled via a spacer. Mean morning and evening PEF values, however, were similar in the two groups while they were taking a dose of 2 mg daily, suggesting that there is probably no difference in clinical efficacy at this dose. Consistent with this is the finding that bronchodilator use and symptom scores were very similar in the groups.
Few adverse effects were associated with high dose inhaled steroid treatment. The incidence of oropharyngeal candidiasis was similar to that previously reported with lower doses.89 Use of the spacer was associated with less throat irritation and clinical candidiasis but did not protect against dysphonia as has been reported.'0 Cough is probably related to aerosol propellants or surfactants and is reduced when steroid is inhaled as dry powder." Spontaneous bruising was rare (4%) and occurred only at doses that caused hypthalamo-pituitary-adrenal suppression. Reports of bruising in patients taking high dose inhaled steroids'21' have come from studies that did not include assessments of adrenal axis function, and it is not clear how this manifestation of the effects of systemic corticosteroid relates to suppression of endogenous steroid production.
In a previous study '4 we found that 24 hour urinary excretion of less than 80 nmol free cortisol and post-tetracosactrin cortisol concentrations below 500 nmol/l both correlated well with abnormal responses to insulin stress testing, widely regarded as the gold standard test for hypothalamo-pituitaryadrenal suppression. In contrast, the 0900 h serum cortisol concentration was a poor screening test. In the present study, however, at diagnosis of hypothalamo-pituitary-adrenal suppression the 0900 h cortisol was below 190 nmol/l in 25 of 29 patients, and this test was similar in sensitivity to the post-tetracosactrin cortisol concentration (<500 nmol/l in 26/29) and urinary free cortisol (<80 nmol/ 24 h in 24/29). The rise in cortisol concentration in response to tetracosactrin proved, as in our previous study, to be a poor discriminator (<200 nmol/l in only 9/29). The difference in the discriminant value of the 0900 h cortisol concentration between this study and the preceding one may be a reflection of the duration of hypothalamo-pituitary-adrenal suppression. The reduction in basal cortisol levels in blood and urine while the rise in cortisol concentration in the tetracosactrin test is preserved indicates that suppression caused by an increase in inhaled steroid is mainly occurring at the level of the hypothalamus or pituitary, or both. As the suppressive influence is maintained atrophy of the adrenal cortex occurs, and the ability of tetracosactrin to stimulate a prompt increase in cortisol secretion is lost. In the previous study'4 the duration of adrenal axis suppression was unknown.
The current data sheet recommendations for the high dose beclomethasone dipropionate inhaler Becloforte state that the maximum daily dose should be 2 mg. This study confirms our earlier finding that 1.5 mg beclomethasone dipropionate daily may be associated with subnormal adrenal axis function in a few patients.3 Hypothalamo-pituitary-adrenal function remained normal, however, in most patients until doses of more than 3 mg a day were taken. The good control of asthma symptoms in most patients taking 2-2-5 mg daily does not permit conclusions to be drawn about whether increasing the dose beyond this is associated with increased therapeutic efficacy. The upper limit of the dose-response curve for beclomethasone dipropionate (and for other inhaled corticosteroids) has not been established and, like susceptibility to hypothalamopituitary-adrenal suppression and other unwanted effects of steroids, is likely to vary widely between individual patients. Tests of hypothalamo-pituitary-adrenal function may be useful for predicting which patients will tolerate higher doses. In less severe exacerbations of asthma a temporary increase in inhaled steroid to 2-5-3 mg daily might be as effective as a short course of oral corticosteroids but associated with fewer long term adverse effects if frequent courses are required.
This study suggests that doses higher than the currently accepted maximum of 2 mg beclomethasone dipropionate daily may be taken by many adults with asthma without causing subnormal hypothalamo-pituitaryadrenal function. Whether these higher doses control asthma symptoms more effectively remains to be established. 
